Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a patch stop Implant-Related bleeding? new trial aims to find out

NCT ID NCT07083635

Symptom relief Sponsor: Chulalongkorn University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a transdermal patch containing ethinyl estradiol and norelgestromin can stop irregular vaginal bleeding in women using contraceptive implants. Forty women over 18 who have abnormal bleeding will apply the patch or a placebo for 21 days. Researchers will check if bleeding stops by day 14 and monitor side effects and recurrence for 3 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ethinyl estradiol and norelgestromin patch
What this could lead to
If it works, this could offer a simple, short-term patch treatment to stop irregular bleeding caused by contraceptive implants.
What could go wrong
This is a small, early-phase trial with only 40 participants. The patch may not work better than placebo, and side effects from hormones are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 18 years and older * Regular menstrual cycles : at least 1 cycle prior to contraceptive implant insertion * Normal pelvic examination and transvaginal ultrasound results * Normal cervical cancer screening within the past 3 years * Irregular vaginal bleeding defined as: Bleeding for more than 8 consecutive days, or Bleeding-free intervals of 15 days or less Exclusion Criteria: * Previous treatment for irregular vaginal bleeding within the past 3 months * Pregnancy * Contraindications to estrogen or progestin use * Allergy to estrogen or progestin * Allergy to hormonal patches * Heavy vaginal bleeding causing anemia symptoms such as: Fatigue/Fainting/Dizziness

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Contraception behavior are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Contraception Behavior menstrual disorder Menstruation Disturbances Metrorrhagia Uterine Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contraception behavior Menstruation disturbances Metrorrhagia Uterine hemorrhage

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Family Planning Clinic, King Chulalongkorn Memorial Hospital

    RECRUITING

    Pathum Wan, Bangkok, 10400, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.